EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
about
Common variation in EMSY and risk of breast and ovarian cancer: a case-control study using HapMap tagging SNPs.BRCA2 suppresses cell proliferation via stabilizing MAGE-D1WDRPUH, a novel WD-repeat-containing protein, is highly expressed in human hepatocellular carcinoma and involved in cell proliferationStructural basis for recruitment of BRCA2 by PALB2Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinomaBS69, a specific adaptor in the latent membrane protein 1-mediated c-Jun N-terminal kinase pathwayBinding of EMSY to HP1beta: implications for recruitment of HP1beta and BS69BRCAness: finding the Achilles heel in ovarian cancerThe Gene Wiki: community intelligence applied to human gene annotationBRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarianEMSY links breast cancer gene 2 to the 'Royal Family'Secretory carcinoma of the breast containing the ETV6-NTRK3 fusion gene in a male: case report and review of the literature.Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerBeyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid TumorsEpigenetic virtues of chromodomainsGermline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomasPredictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized MedicinePreventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer TherapyMolding BRCA2 function through its interacting partnersDSS1 is required for the stability of BRCA2Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forksBRCA2 is required for neurogenesis and suppression of medulloblastomaHomologs of breast cancer genes in plantsPARP inhibitor treatment in ovarian and breast cancerThe genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsHallmarks of 'BRCAness' in sporadic cancersExtensive crosstalk between O-GlcNAcylation and phosphorylation regulates cytokinesisMolecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.DNA double strand break repair and its association with inherited predispositions to breast cancerOvarian cancer: linking genomics to new target discovery and molecular markers--the way ahead.Physical Confirmation and Comparative Genomics of the Rat Mammary carcinoma susceptibility 3 Quantitative Trait LocusSystematic discovery of novel eukaryotic transcriptional regulators using sequence homology independent predictionEMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases.Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.Future of personalized medicine in oncology: a systems biology approach.An entire exon 3 germ-line rearrangement in the BRCA2 gene: pathogenic relevance of exon 3 deletion in breast cancer predispositionGene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.Deletion of BRCA2 exon 27 causes defects in response to both stalled and collapsed replication forksDrosophila SIN3 isoforms interact with distinct proteins and have unique biological functions.
P2860
Q21260438-9FCE51EB-EFBA-4088-AFB7-66D2E09C4C15Q24304364-EB5B5164-65A5-421E-87E4-0BD522C9CD7FQ24305671-75ADB2F6-E2AE-404B-9286-9FBF92D70EB1Q24315745-7473CC83-B90C-4E03-BAC7-810B40410438Q24536023-B6DE1F91-1E51-448B-A5AB-B9102F2EE24FQ24537608-DE026CE7-0CE9-4B68-B645-F9F707CF60C2Q24539082-663B0B4F-B35E-4DC6-B5EB-926AD516AD7EQ24630872-D9F2F70C-AD4F-4413-8C23-C6B93366B6D6Q24644366-76987FC1-B715-4626-A7AA-8E4EA87D8475Q24672251-CE262FDE-89DD-4FC0-893B-B4009CDB3380Q24806435-BAC6416E-E654-45D3-82F6-7BA0B8FFB0AFQ24812385-E705C873-8766-4358-A904-768A2E4FCD66Q26783551-4A3F806A-41AE-495E-9D1B-288324E255FBQ26852274-D0F6EFA9-2E74-403B-9648-62C3C1502D7BQ27016161-A13BA084-8251-49D0-9962-F0516077DAD6Q27852671-138D8D83-5984-4987-B09A-5DE1E74D08D4Q28072204-B3F20540-F9AD-4A6B-AE80-3C260EE4DAB4Q28084568-8F21C593-CC0E-4833-963B-FC1C69D6F608Q28085603-299F0594-1F0B-4E70-944B-412DB2B47BA8Q28115992-101F2C1A-4B2C-4ED4-AD1A-2D3F9D3DFC77Q28294399-69A1A458-B2EA-4A3C-9517-53B8D2F055B6Q28590758-C88395F7-7913-4666-8A8A-BC2D0161C1CFQ28729894-939B74C4-B33A-4305-9927-2D3A82117E82Q28741688-A6B47974-DF15-4F0F-9FD4-A01CB5D4CB81Q29614700-4E8B5716-10AF-4D1F-AFC6-1C69AD2056A1Q29618825-A110DBE7-3C63-439E-8F09-0C8778C879FFQ30436151-E746C8AE-A432-4E69-A666-06C7C779A173Q30448232-6C0FE8AC-5C91-4D90-8C7F-FF972A62ED5BQ33557369-A44E90D2-245B-4115-A43D-9AC05A722680Q33732268-BB466C5E-7EC2-4AAE-95FA-5B34170B914FQ33748323-EF24112D-E2EB-4FBE-96AA-5B0886B5EEC2Q33807637-55F9F1D4-8767-435F-BBFA-3126A73A3FDFQ33837744-CB0E4210-501D-4954-B78C-D39CA73342B3Q33848050-C5436A42-F26F-4AA6-BCC5-21968EC9AD1EQ33851843-C0AD4C5C-22A6-4D30-BD91-13E5C6F6FB7FQ33898189-12A8AD0F-3392-4EED-AA99-1F409D5374F6Q34027876-855B88A4-7C5A-49C5-B4FF-24BDB2162154Q34049228-4CBEFC04-A3E4-4DB9-87D8-AEF4B81868BCQ34061263-A5FB115C-53C3-4C0F-9C1E-65D3A6473899Q34094666-68EE6E2B-0F51-404E-AE29-8B102A43DD28
P2860
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
description
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2003
@ast
im November 2003 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 26 November 2003)
@en
vedecký článok (publikovaný 2003/11/26)
@sk
vědecký článek publikovaný v roce 2003
@cs
wetenschappelijk artikel (gepubliceerd op 2003/11/26)
@nl
наукова стаття, опублікована в листопаді 2003
@uk
مقالة علمية (نشرت في 26-11-2003)
@ar
name
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
@ast
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
@en
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
@en-gb
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
@nl
type
label
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
@ast
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
@en
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
@en-gb
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
@nl
prefLabel
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
@ast
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
@en
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
@en-gb
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
@nl
P2093
P50
P3181
P1433
P1476
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer
@en
P2093
Aidan Doherty
Anthony Cahn
Ashok Venkitaraman
Blake Gilks
Bruce Ponder
David Bentley
David Huntsman
David S Yu
E S Jordanova
Edward Schuuring
P304
P3181
P356
10.1016/S0092-8674(03)00930-9
P407
P577
2003-11-26T00:00:00Z